Cédric POIGNEAU, President-CEO, who will design the drug candidate's development strategy based on regulatory requirements and key administrative functions. Cédric, who is qualified as a chartered accountant, will bring his expertise in management and pharmaceutical development to the project.
Isabelle Pelletier-Bressac, CEO of Gustave Roussy Transfert, has a tranning in Law from Paris and Stockholm univeristies. Prior joining IGR, Isabelle has worked for SANOFI, GENSET and Cellectis in Business development department.
Jean-François Dufour-Lamartinie is R&D /Clinics Director at Hybrigenics. He has extensive experience in clinical drug development. Before joining Hybrigenics, Jean-François Dufour-Lamartinie served for 3 years in a similar capacity in BioAlliance Pharma, a French biopharmaceutical company.
Alain Maquîn , Chief Pharmaceutical Officer (CPO) and General Manager at ASTERA (Eurodep Exploitant) Company specialized in Outsourcing pharmaceutical services.
Degree in Pharmacy, master's degrees in Galenic technology and Health economy. He has an extensive experience in leading domestic and international pharmaceutical or emerging biotech companies (Sanofi, LFB, Mediolanum, BioAlliance, Dômes Finance and Idis)
Elyes Chouaieb, Pharm,
fellowship at NIH, Bethesda, USA, she was recruited to INSERM to continue her research at Gustave Roussy Institute.
During her career, she was initially interested in the murine immunoglobulin genes and then in human T lymphocytes receptors. Since 1996 she has directed her research towards anti-tumor immunology and immunotherapy.
She has contributed to the identification of tumor associated antigens in lung cancer that are recognized by cytotoxic T lymphocytes and has helped elucidate the mechanisms involved in optimizing the anti-tumor immune response.
Research director at INSERM, Ecole Normale, Fathia Mami-Chouaib obtained a PhD in immunology from the Pasteur Institute in Paris in 1984. After a 3-year post-doctoral
A scientific advisory committee has been established to assist the company to define its scientific strategy for the successful development of these pharmaceuticals. It is chaired by Dr. Fathia MAMI-CHOUAIB and comprises:
• Dr. Peter G. COULIE, MD , PhD, Catholic University of Leuven, Belgium
• Professor Pedro ROMERO MD, Deputy Director of the Ludwig Center UNIL for Cancer Research, Lausanne Switzerland.
• Dr. Benjamin BESSE, MD, Chief of Thoracic Pathology Committee of the Institut Gustave Roussy in Villejuif, France
• Jean-François Dufour-Lamartinie, MD is R&D and Clinics studies Director at Hybrigenics, France.
• Alain Maquîn, Pharm , Chief Pharmaceutical Officer (CPO) and General Manager at ASTERA (Eurodep Exploitant) Company specialized in Outsourcing pharmaceutical services.
Other scientific and medical experts are expected to complete the committee.
